[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertise Here
October 10, 2011
Volume 89, Number 41
p. 11

Contract Research: Pharmaceutical Product Development to go private in $3.9 billion deal

Rick Mullin

  • Print this article
  • Email the editor

Latest News

October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Pharmaceutical Product Development (PPD) has agreed to be purchased by the private equity firms Carlyle Group and Hellman & Friedman in an all-cash transaction valued at $3.9 billion. On completion of the deal, heralded as a sign of things to come in the contract research sector, PPD will become a private company.

With sales last year of $1.5 billion, PPD is one of the world’s largest pharmaceutical contract research organizations.

PPD, in recent years, has extended its scope to cover a broad range of drug discovery and development services. In 2009, for example, PPD acquired BioDuro, a California-based drug discovery services firm employing about 660 chemists and other research staff, mainly in Beijing.

Lauren Migliore, a stock analyst with Morningstar, tells C&EN that the breadth of services offered by PPD is part of what attracted the private investors. “Having early discovery through Phase IV services is one of the primary reasons why PPD has been so successful at winning new business and landing long-term strategic partnerships,” she says.

Migliore anticipates more deals in the contract research sector, where the last major player to be taken private, Quintiles, was acquired by its founder and a team of private investors in 2003. She says larger players like Covance, Parexel, and Charles River are poised for growth based on increased outsourcing by pharmaceutical firms, as well as market share gains at the expense of their smaller peers.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!